Loading...
NPI 1659337459 · Las Vegas, NV · Pain Medicine (Anesthesiology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Steven Kozmary is a pain medicine (anesthesiology) physician provider located in Las Vegas, Nevada. This profile covers 21 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Steven Kozmary |
| Address | 2851 El Camino Ave |
| City | Las Vegas |
| State | NV |
| ZIP | 89102 |
| Taxonomy | Pain Medicine (Anesthesiology) Physician |
| NPI Enumerated | April 21, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.3M |
| Medicaid | $229.6K |
This provider’s billing is heavily Medicare-weighted by scale: Total Medicare revenue is $1.3M versus Total Medicaid revenue of $229.6K, indicating Medicare dominates the practice’s revenue base rather than an even payer mix. The magnitude gap suggests most of this provider’s reimbursed activity is realized through Medicare relationships.
Medicare revenue is extremely concentrated in a few toxicology and testing codes: the top three Medicare codes account for 92.8% of Medicare revenue, driven primarily by G0480 ($776.9K, 58.1%) and 80307 ($427.2K, 31.9%). This mix indicates the provider’s Medicare business is largely laboratory/toxicology-focused rather than procedure- or E/M-centric.
Medicaid revenue is similarly concentrated: the top three Medicaid codes account for 91.2% of Medicaid revenue, with G0480 ($125.5K, 54.6%), 99214 ($47.4K, 20.6%), and 80307 ($36.7K, 16.0%) together making up most Medicaid receipts. Compared with Medicare, Medicaid shows a larger proportional contribution from E/M visits (99214) which implies a somewhat different service mix or payer routing for non-Medicare patients.
The provider’s national competitive standing for drug testing is prominent on Medicare but modest in-state for Medicaid. On Medicare, G0480 ranks #19 of 1590 providers (99th percentile; extreme outlier) and 80307 ranks #31 of 4760 providers (99th percentile; notably above typical national volume), signaling unusually high national-level volume for definitive and presumptive drug testing; by contrast, in-state Medicaid ranks for G0480 (#21 of 49, 58th percentile) and 80307 (#85 of 149, 43rd percentile) are typical to modest, indicating the high testing volumes show up primarily in Medicare cohorts.
Service-line mix is specialized: billing is dominated by definitive and presumptive drug testing (G0480, 80307 and presence of G0483) alongside a non-trivial footprint of cognitive testing (96132) and occasional interventional pain procedures (e.g., 64493, 64483). The presence of 96132 (314 Medicare claims, $27.9K revenue; ranks #71 of 3173, 98th percentile; notably above typical national volume) suggests the practice also invests in neuropsychological testing capacity in addition to toxicology services.
Although the provider performs interventional codes typical of a pain medicine taxonomy, those procedures represent a small share of revenue on Medicare (examples: 64493 $14.4K, 1.1%; 64483 $6.9K, 0.5%), reinforcing that the operational profile is dominated by testing and office-based evaluation rather than high-volume procedural interventions. This disparity between service types should inform network valuation and procedural access expectations.
Tenure is long-standing: NPI enumerated 2006-04-21 (~20 years ago), indicating a mature billing history and an established presence in the market. Longevity combined with concentrated testing revenue suggests an established operational model likely centered on sustained toxicology throughput.
The high revenue concentration in a few codes and the asymmetric payer profile warrant attention for contracting and utilization oversight: Medicare testing revenues (notably G0480 and 80307) form the bulk of income (top three Medicare codes = 92.8%), while Medicaid delivers a smaller, differently composed revenue stream (top three Medicaid codes = 91.2%). Payers and analyst teams should prioritize review of coding mix, encounter routing, and utilization management for definitive and presumptive drug testing when assessing network value or risk for this provider.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6,940 | $110 | $776.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 7,000 | $60 | $427.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 390 | $100 | $37.3K |
| 96132 | The provider, a physician or other qualified healthcare professional, spends up to one hour administering neuropsychological tests, which includes time spent face–to–face with the patient in… | 310 | $90 | $27.9K |
| 64493 | The provider injects a diagnostic or therapeutic substance into a single lumbar or sacral paravertebral facet (zygapophyseal) joint, or into the nerves that supply that joint, using imaging guidance… | 100 | $150 | $14.4K |
| 64483 | This procedure is the injection of an anesthetic agent and/or steroid in the form of a transforaminal epidural injection into a single level (either lumbar or sacral). | 30 | $250 | $6.9K |
| 77002 | The provider uses fluoroscopic guidance to place a needle for biopsy, aspiration, injection, or localization of a device to detect any lesions in any area of the body, except for the spine, or to… | 70 | $90 | $6.6K |
| 64494 | In this add–on procedure, the provider injects a diagnostic or therapeutic substance into a single lumbar or sacral paravertebral facet (zygapophyseal) joint, or into the nerves that supply that… | 80 | $70 | $5.9K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 40 | $130 | $5.1K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 70 | $70 | $5.1K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0480 | 1 | 10 | 230 | $110 | $118.9K |
| G0481 | 14 | 20 | 130 | $150 | $74.5K |
| 64635 | 74 | 80 | 40 | $440 | $25.2K |
| 80307 | 1 | 110 | 100 | $60 | $21.9K |
| 64483 | 72 | 100 | 60 | $230 | $20.3K |
| 99214 | 633 | 3,610 | 110 | $80 | $19K |
| 64493 | 23 | 80 | 50 | $210 | $17.1K |
| J3490 | 46 | 50 | 60 | $90 | $12.7K |
| 64490 | 27 | 50 | 30 | $220 | $10.5K |
| 99213 | 1,778 | 3,500 | 80 | $60 | $10K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,720 | $70 | $125.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 470 | $100 | $47.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 990 | $40 | $36.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 160 | $70 | $10.5K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 50 | $150 | $7K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 30 | $90 | $2.7K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 34 | 40 | 530 | $70 | $561K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 85 | 150 | 1,440 | $20 | $193.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 21 | 50 | 910 | $40 | $164K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 927 | 2,250 | 290 | $60 | $138K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,596 | 2,480 | 330 | $50 | $107.6K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 499 | 780 | 90 | $100 | $46.6K |
Other providers in the same ZIP code as Steven Kozmary, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.